Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr1.27
>-kr0.01(-0.47%)
At close: 4:00 PM EDT
kr1.27
>-kr0.01(-0.47%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume77.75K
Average Volume (3M)373.34K
Market Cap
kr432.83M
Enterprise Valuekr135.56
Total Cash (Recent Filing)kr145.63M
Total Debt (Recent Filing)kr357.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)kr17.70M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetLow leverage and a sizeable equity base give Intervacc financial flexibility lasting months to fund commercialization, regulatory work, or R&D without immediate refinancing. This reduces solvency risk and supports strategic optionality while the business scales its vaccine franchise.
Commercialized Core Product (Strangvac)Having an approved, commercial vaccine (Strangvac) creates a durable revenue foundation tied to veterinary adoption and distribution partnerships. A marketed product shortens time-to-revenue vs earlier-stage peers and anchors commercial scale and partner-led geographic expansion over the coming months.
Improving Free Cash Flow TrendAlthough still negative, a ~48% improvement in free cash flow signals better cash conversion and operational discipline. If the trend continues, it materially reduces financing needs and supports longer runway, making current business actions more sustainable over a 2–6 month horizon.
Bears Say
Heavy Cash BurnSustained large negative operating and free cash flow requires external funding or dilutive financing to sustain operations. Over months this constrains the company’s ability to invest in sales, manufacturing scale-up or regulatory work and increases execution risk if capital markets or partners delay support.
Negative Gross Profit And Massive LossesNegative gross profit indicates product economics or cost structure currently fail to cover direct costs; coupled with very large operating losses, this undermines margin sustainability. Without durable improvement, losses will erode equity and limit reinvestment capacity over the medium term.
Modest, Declining RevenueLow absolute revenue and a recent YoY decline reflect limited scale and inconsistent commercial traction. Reliance on a small revenue base increases sensitivity to partner terms or regional uptake, making durable growth and margin recovery more uncertain over the next several months.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr432.83M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 22 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -kr0.06 earnings per share for the quarter, the consensus estimate of -kr0.06 by kr0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.05.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, expectations of -kr0.06. Following the earnings report the stock price went down -14.82%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―